Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study-Reference-Cited by-同舟云学术

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

Published:2011-12 Issue:9808 Volume:378 Page:2005-2012
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Pavel Marianne E,Hainsworth John D,Baudin Eric,Peeters Marc,Hörsch Dieter,Winkler Robert E,Klimovsky Judith,Lebwohl David,Jehl Valentine,Wolin Edward M,Öberg Kjell,Van Cutsem Eric,Yao James C

Publisher

Elsevier BV

Subject

General Medicine

Reference24 articles.

1. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States;Yao;J Clin Oncol,2008

2. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors;Saltz;Cancer,1993

3. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group;Rinke;J Clin Oncol,2009

4. Biomarker development for the clinical activity of the mTOR inhibitor everolimus (RAD001): processes, limitations, and further proposals;O'Reilly;Translational Oncol,2010

5. Targeting the mTOR signaling network for cancer therapy;Meric-Bernstam;J Clin Oncol,2009

Cited by 888 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of metastatic pheochromocytomas and paragangliomas: when and what;Current Problems in Cancer;2024-08

2. MODERN ASPECTS OF CARCINOID BRONCHOPULMONARY TUMOURS DIAGNOSIS AND TREATMENT;Clinical and Preventive Medicine;2024-07-18

3. Update in the management of gastroenteropancreatic neuroendocrine tumors;Cancer;2024-07-16

4. European Neuroendocrine Tumor Society (ENETS) 2024 guidance paper for the management of well‐differentiated small intestine neuroendocrine tumours;Journal of Neuroendocrinology;2024-07-08

5. Factors Predicting Prognosis in Metastatic Grade 1 Gastro-entero-pancreatic Neuroendocrine Tumors;Journal of Gastrointestinal Cancer;2024-06-14